logo
  

SiTime Stock Rises As Q1 Loss Narrower Than Street Estimates

Stock of SiTime Corp. (SITM) is climbing over 29 percent on Thursday morning after the company reported a first-quarter loss that was narrower than Street estimates.

For the quarter, loss stood at $28.7 million or $1.26 a share compared to last year's $19.9 million or $0.89 a share in the first quarter.

Excluding special items, the company revealed a loss of $1.9 million or $0.08 per share compared with profit of $5.5 million or $0.24 per share in year-ago quarter.

However, analysts surveyed by Thomson Reuters estimated a loss of $0.15 per share. Analysts' estimates typically exclude special items.

Revenue declined to $33.02 million from $42.4 million in previous year.

Currently, SiTime's stock is moving up 29.31 percent, to $125.33 over previous close of $96.92 on the Nasdaq. It has traded between $72.39 and $141.99 for the past one year.

For comments and feedback contact: editorial@rttnews.com

Business News

Looking to Invest in the Best Biotech Stocks? Subscribe to RTT Biotech Investor.
Editors Pick
Microsoft has launched a new category of Windows PCs designed for Artificial Intelligence (AI) that are slated to be the fastest and most intelligent Windows PCs ever built. The Copilot+ PCs come with built-in AI hardware and will support AI features across the operating system. Hospira, Inc., affiliated to dug major Pfizer Inc., is recalling select lots of Buprenorphine Hydrochloride Injection Carpuject Units and Labetalol Hydrochloride Injection Carpuject Units, according to the U.S. Food and Drug Administration. The recall was initiated due to the potential for incomplete crimp seals. The company has received one customer complaint for one leaking unit. While reporting financial results for the first quarter on Wednesday, off-price retailer TJX Companies, Inc. (TJX) provided its earnings and comparable store sales outlook for the second quarter and raised earnings outlook for the full-year 2024. For the second quarter, the company now expects earnings...

In this week's video, we highlight Roche's pioneering approach for weight loss and glucose control. Meanwhile, the EMA has taken strict action on certain preterm birth drugs and Bayer has downsized its staff. In a breakthrough for cancer treatment, the FDA has approved a groundbreaking T-cell engager therapy. Amid progress, setbacks emerge as another ALS drug study has faltered, following closely on the heels of Amylyx Pharma's recent decision to withdraw its FDA-approved ALS drug, Relyvrio.

View More Videos
RELATED NEWS
Follow RTT